phase iii trials complete - data awaited, page-21

from my understanding you are right in that they have the rights for the use in children.

the question is the definition of that is a child and what is an adult? Then when you look at the % of cases with children against that in adults. Its clear that the case with adults is very low.

therefore, would a company look to spend money to get the rights from PP for adults only..unlikely and from that point it would make sense for EMS to the rights for all patients if viable in relation that there has been no clinical work and if they can at a low cost just extrapolate the finding out to cover a larger body mass and dosage levels

but again it looks like nothing ever came from the US meeting